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Abstract
Phenylbutyrate (PB) is a histone deacetylase inhibitor
that has been shown to induce differentiation and
apoptosis in various cancer cell lines. Although these
effects are most likely due to modulation of gene
expression, the specific genes and gene products
responsible for the effects of PB are not well charac-
terized. In this study, we used cDNA expression arrays
and Western blot to assess the effect that PB has on the
expression of various cancer and apoptosis-regulatory
gene products. We show that PB attenuates the
expression of the apoptosis antagonist Bcl-XL, the
double-strand break repair protein DNA-dependent
protein kinase, the prostate progression marker caveo-
lin -1, and the pro-angiogenic vascular endothelial
growth factor. Furthermore, PB was found to act in
synergy with ionizing radiation to induce apoptosis in
prostate cancer cells. Taken together, our results point
to the possibility that PB may be an effective anti -
prostate cancer agent when used in combination with
radiation or chemotherapy and for the inhibition of
cancer progression. Neoplasia (2001) 3, 331–338.
Keywords: histone deacetylase inhibitor, apoptosis, radiosensitizer, invasion,
angiogenesis.
Introduction
Phenylbutyrate (PB) is a short -chain fatty acid that induces
differentiation and apoptosis in a number of cell lines including
prostate cancer cells [1,2 ] . The mechanism of action of
butyrate and butyrate derivatives involves inhibition of the
histone deacetylase activity in cells, leading to chromatin
modifications and the reprogramming of gene expression [3–
7] . Histone deacetylase inhibitors have been shown to
upregulate the expression of the cell cycle inhibitor p21WAF1
[8,9 ] , the CD86 receptor involved in tumor immunogeneity
[10] , and the estrogen [11] and androgen [12] receptors.
Butyrate and butyrate derivatives have also been shown to
downregulate some genes and gene products such as the
apoptotic antagonists Bcl -2 [13–15] and Bcl -XL [16] , and
urokinase involved in tumor cell invasiveness [17,18] .
Due to its low toxicity in vivo and its apoptosis- and
differentiation- inducing activity towards cancer cells, PB and
other butyrate derivatives have been considered as potential
anticancer agents [19–21] . It has been shown that PB
reduces the growth of human prostate cancer xenographs in
laboratory animals [2 ] . Moreover, butyrate may act as a
chemopreventive agent against colon cancer [22] . As
dietary fibers get fermented by bacteria in the bowel,
millimolar concentrations of butyrate are liberated, which is
thought to lead to the selective elimination of neoplastic
colonic cells by apoptosis [22] . Dietary butyrate has also
recently been shown to inhibit nitrosomethylurea- induced
mammary cancer in the rat [23] .
We have previously reported that butyrate attenuates the
expression of the apoptosis antagonist BCL-XL in human
fibroblasts and acts in synergy with ionizing radiation and
cisplatin to induce apoptosis [16] . In this study, we show that
at clinically achievable doses, PB attenuates the expression
of Bcl -XL, DNA-dependent protein kinase (DNA-PK),
caveolin-1, and vascular endothelial growth factor (VEGF).
The downregulation of Bcl -XL and DNA-PK by PB correlated
to an enhanced sensitivity towards radiation- induced apop-
tosis in prostate cancer cells. These results suggest the
possibility that PB may be a useful anticancer agent when
combined with radiation or chemotherapy and against the
progression of prostate cancer.
Materials and Methods
Cell Culture
Human PC3, DU-145, and LNCaP cell lines were
obtained from American Type Culture Collection (Manassas,
VA) and were maintained by in vitro culture at 378C in a
humidified atmosphere containing 5% CO2 in air. Both the
PC3 and DU-145 cell lines were grown in MEM (Life
Technologies, Grand Island, NY) supplemented with 10%
Neoplasia . Vol. 3, No. 4, 2001, pp. 331 –338
www.nature.com/neo
331
Abbreviations: DNA -PK, DNA - dependent protein kinase; VEGF, vascular endothelial
growth factor; PB, phenylbutyrate
Address all correspondence to: Dr. Mats Ljungman, Department of Radiation Oncology,
Division of Radiation and Cancer Biology, 4306 CCGC, 1500 East Medical Center Drive,
Ann Arbor, MI 48109 - 0396. E-mail: ljungman@umich.edu
1This work was supported by a Career Development grant and a Student Development
award from the NIH /NCI prostate SPORE grant, University of Michigan.
Received 30 January 2001; Accepted 5 March 2001.
Copyright# 2001 Nature Publishing Group All rights reserved 1522-8002/01/$17.00
RESEARCH ARTICLE
fetal bovine serum (Hyclone, Logan, UT) , whereas the
LNCaP cell line was grown in RPMI-1640 (Life Technolo-
gies) supplemented with 10% fetal bovine serum. Cells were
plated 2 days prior to experiments on 100-mm culture
dishes. Cells were about 50% to 70% confluent at the time of
the experiments.
RNA Isolation
PC3 cells were treated with 2 mM PB for 18 hours.
Following treatment, the dishes were washed with PBS prior
to extraction of total RNA from control and treated PC3 cells
using TRIZol Reagent according to instructions from the
manufacturer (Life Technologies) .
cDNA Array Hybridization
Assessment of differentially expressed genes in mock- or
PB-treated PC3 cells was performed using the Atlas Human
Cancer cDNA Expression Array (Clontech, Palo Alto, CA).
Following DNase I digestion of the isolated total RNA,
[ -32P] - labeled probe synthesis was undertaken by
reverse transcription using the protocol specified in the
Clontech manual. The labeled probes were then hybridized
to the cDNA filter overnight at 688C in ExpressHyb buffer
(Clontech) . After stringent washing at 688C, filters were
analyzed by phosporimaging (Phosphorimager SI; Molec-
ular Dynamics, Sunnyvale, CA). Data analysis was per-
formed using Phosphorimager scans and computational
analysis provided by AtlasImage analysis software (Clon-
tech) . The data were normalized to the expression of tubulin
and ubiquitin. Similar results were obtained when the data
were normalized to all the housekeeping genes or total array
expression.
Western Blot Analysis
The treated prostate cancer cells were rinsed in PBS,
detached by scraping, and collected by centrifugation. The
collected cells were lysed by boiling in 100 L lysis buffer
(2% SDS, 10% glycerol, and 62.5 mM Tris, pH 6.8) .
Samples were subsequently sonicated for 10 seconds
using a microtip (Heat Systems-Ultrasonics) . Protein
concentration was quantified using the Biorad protein
assay. To 30 g protein solution was then added 2-
mercaptoethanol and bromophenol blue to 5% and 0.05%,
respectively. After a 5-minute boiling, the proteins were
separated on 15% SDS-PAGE gels for analysis of Bcl -XL
or caveolin-1 or 6% SDS-PAGE gels for analysis of DNA-
PK. Protein molecular weight markers were loaded in a
separate lane (Biorad, Hercules, CA). After electropho-
retic separation, the proteins were transferred to poly-
vinylidene difluoride membranes (Millipore, Bedford, MA).
Following blocking of the membranes with 5% dry milk
solution (Kroger, Ann Arbor, MI) for 2 hours, they were
incubated overnight with anti–caveolin -1, anti–Bcl -XL
(Transduction Laboratories, Lexington, KY), or anti–
DNA-PK (BD PharMingen, Research Triangle Park, NC)
antibodies. Horseradish peroxidase–conjugated anti -
mouse secondary antibody (Oncogene Research Prod-
ucts, Boston, MA) and enhanced chemiluminescence
(SuperSignal CL; Pierce, Rockford, IL) were used to
together with X-ray film to visualize the protein bands.
Sample loading was normalized to  -actin expression
(anti– -actin AC-74; Sigma). The quality of total protein
transfer was assessed by staining blots with Coomassie
brilliant blue following exposure of the membranes to X-ray
film. Images were scanned using a flatbed scanner
(UMAX) and analyzed using NIH Image software.
Analysis of VEGF Protein Levels in Sample Media
PC-3, DU-145, and LNCaP cells were seeded on 100-
mm dishes. When the plates were approximately 60% to
70% confluent, the media was exchanged for fresh media
and the cells were either mock- treated or incubated with
100 M CoCl2 to simulate a hypoxia- like state. To half of
the plates, 2 mM PB was added. Following PB treatment for
24 hours, the conditioned media was collected, centrifuged
at 6000 rpm for 6 minutes to remove cellular debris, and
then stored at 208C. To calculate the total number of cells
per plate, the remaining attached cells were scraped off the
plates and an aliquot of the cell suspension was counted
using a Coulter counter (Coulter Electronics, Hialeah, FL) .
Samples stored at 208C were then thawed and VEGF
concentrations were determined using the Quantikine
human VEGF Elisa Kit (R&D Systems, Minneapolis, MN).
Samples were diluted 1:10 in a dilution solution provided
with the ELISA kit. The readings of the VEGF concentration
in conditioned media were then expressed as the amount of
VEGF in picograms per milliliter per 106 cells. For each set
of conditions, the %VEGF was compared to the mock-
treated sample, values of which were set to 100%.
Quantification of Apoptosis
Cells were treated with 2 Gy of ionizing radiation and then
incubated in the presence or absence of 2 mM PB for 72
hours. Both floating and attached cells ( trypsinized) were
collected by centrifugation (1000g for 10 minutes) , fixed in
ethanol, and the cellular DNA was stained with propidium
iodide as previously described [16,24] . Cells with sub-G1
DNA content were scored as apoptotic using flow cytometry
(Coulter Elite ESP Cell Sorter, Miami, FL) and the Multicycle
software package (Phoenix Flow Systems, San Diego, CA).
Results
Butyrate and PB Inhibit the Expression of Bcl -XL in PC3
Cells
We have previously shown that butyrate reduces the
expression of Bcl -XL in human fibroblast cells to about 70%
and 40% following a 24-hour incubation with either 5 or 10
mM butyrate, respectively [16] . This attenuated Bcl -XL
expression correlated with a sensitization of the cells to
radiation- and chemotherapy- induced apoptosis. Here we
investigated whether butyrate and its derivative PB could
lower the protein levels of Bcl -XL in the prostate cancer cell
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line PC3. Our results show that the cellular levels of Bcl -XL in
PC3 cells were reduced to about 20% and 10% following 24
hours of incubation with 2 or 5 mM butyrate, respectively
(Figure 1A and C ) . Incubation of PC3 cells with 2 or 5 mM
PB inhibited the expression of Bcl -XL to about 40% and 15%,
respectively (Figure 1B and C ) . Butyrate and PB similarly
attenuated the expression of Bcl -XL in DU-145 and LNCaP
cells (data not shown). Thus, our results show that PB can,
like butyrate, attenuate the protein levels of Bcl -XL in
prostate cancer cells. Furthermore, butyrate appears to
reduce the Bcl -XL levels in the prostate cancer cell lines at
lower doses than we previously found necessary to reduce
Bcl -XL in diploid human fibroblasts [16] .
The mechanism of inhibition of Bcl -XL expression by PB
observed in this study may be transcriptional [5 ] or due to
caspase-mediated cleavage of the Bcl -XL protein [25] .
However, reverse transcription polymerase chain reaction
experiments did not detect a transcriptional affect of PB on
the Bcl -XL mRNA levels, nor did we observe cleavage
products of the Bcl -XL protein on Western blots (data not
shown). Thus, the mechanism by which PB reduces the Bcl -
XL levels in prostate cancer cells needs to be elucidated.
PB Affects the Gene Expression Profile in PC3 Cells
To explore the effect of PB on the gene expression profile
in PC3 cells, we used the Atlas human cancer cDNA
expression array from Clontech to analyze the abundance of
specific mRNAs in mock- or PB-treated cells. As can be
seen in Figure 2, treatment with 2 mM PB resulted in the
increased expression of numerous genes. This is to be
expected because PB is a histone deacetylase inhibitor that
would reverse the histone deacetylase–mediated suppres-
sion of transcription of certain genes [26,27] . We note that
the p21WAF1 and interleukin-6 ( IL-6) genes are greatly
upregulated by PB (Figure 2 ) , as previously reported for
other cells incubated with histone deacetylation inhibitors
[8,28] . Taking the average of two independent array
experiments using RNA isolated from two independent
experiments, the signal for the p21WAF1 and IL-6 genes
increased following PB exposure to 521% (S.E.M.±4) and
603% (S.E.M.±103) , respectively. A few genes were found
to be downregulated by PB. One of these genes was DNA-
PK, the gene product of which is an important component of
the DNA double-strand break repair machinery [29,30] .
Another gene was caveolin-1, which in some cancers is
considered a tumor-suppressor gene [31] but appears to be
involved in the progression of the metastatic development in
prostate cancer [32] . Finally, the VEGF gene was down-
regulated in PC3 cells by PB. VEGF is an important factor
involved in tumor angiogenesis [33] . The expression of
DNA-PK, caveolin-1, and VEGF decreased to 37%
(S.E.M.±8) , 18% ( interpretable data from only one experi-
ment was obtained) , and 59% (S.E.M.±3) , respectively.
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Figure 1. The cellular level of Bcl -XL is reduced in PC3 cells by treatment with
butyrate or PB. (A ) PC3 cells were mock - treated (control ) or exposed to 2
or 5 mM butyrate for 24 hours before being collected and the level of Bcl -XL
protein determined by Western blotting. (B ) Same as (A ) but cells were
treated with PB. (C ) The bands in (A ) and (B ) were scanned and quantified
using NIH Image 1.62. Following normalization to the actin levels, the values
were expressed relative to the untreated control cells. These blots are
representative of at least four similar experiments.
A
B
Figure 2. Effect of PB on the gene expression profile in PC3 cells. (A ) Mock -
treated PC3 cells. (B ) PC3 cells treated with 2 mM PB for 18 hours. Whereas
the expression of the IL - 6 and p21WAF1 genes was upregulated by PB
treatment, DNA -PK, caveolin - 1, and VEGF gene expression decreased.
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PB Inhibits the Protein Expression of DNA-PK and
Caveolin-1 in Prostate Cancer Cells
Because DNA-PK and caveolin-1 could potentially act as
useful therapeutic targets for prostate cancer treatment, we
wanted to further explore whether the reduced gene
expression following treatment with PB translated into a
lower protein expression. Using Western blot technique
combined with specific antibodies and chemiluminescence
detection, we show that PB greatly reduced both DNA-PK
and caveolin-1 protein levels in PC3, DU-145, and LNCaP
prostate cancer cells (Figure 3 ) . Following a 48-hour
incubation with 2 mM PB, the protein levels of DNA-PK
were reduced to 17%, 1%, and 25% in PC3, DU-145, and
LNCaP cells, respectively. The corresponding numbers for
caveolin-1 were 23%, 15%, and 19%, respectively. In
contrast, the protein levels of actin were not affected by PB
and we found that p21WAF1 protein levels increased by PB as
previously described using other cancer cells [34–36] .
It has been shown that DNA-PK is a substrate for
caspase-3 during apoptosis [37] . However, we do not
believe that this mechanism was responsible for the loss of
DNA-PK following PB treatment because 1) we only used
attached cells that did not yet display any apoptotic
characteristic and 2) we did not observe the cleavage
products expected to be induced by caspase-3 [37] .
Because the reductions observed in the protein levels of
DNA-PK and caveolin-1 are similar to the reductions found
in mRNA expression (Figure 2 ) , the mechanism by which
PB attenuates the expression of these proteins is most likely
regulated at the level of transcription.
We next investigated whether the suppressing effect that
PB had on the protein expression of Bcl -XL and caveolin-1
was reversible; we allowed cells treated with PB to recover in
drug- free media for 24 hours prior to the analysis of protein
content. It was found that PB-treated PC3 or DU-145 cells
fully recovered the protein expression of Bcl -XL following a
24-hour chase in drug- free media (Figure 4A and B ) .
However, we did not observe a similar recovery of the
expression of caveolin-1 in DU-145 cells (Figure 4C ) . Thus,
the reversibility of the suppressive effect that PB has on
protein expression may be gene- or gene product – specific.
Figure 3. Expressions of DNA -PK and caveolin - 1 proteins are down-
regulated in prostate cancer cells. (A ) PC3, DU-145, and LNCaP cells were
mock - treated or incubated with 2 mM PB for 48 hours. Western blots show
that DNA-PK protein levels are reduced by PB. The blots in (A ) are
representative of blots from three independent experiments. (B ) The bands
in (A ) were scanned and quantified using NIH Image 1.62 and, following
normalization to the actin levels, expressed relative to the untreated control.
(C ) Cells were treated as in (A ) . Western blots show that caveolin - 1 protein
levels are reduced by PB. (D ) Quantification of the bands in (C ) was
performed as described in (B ) . The blots in (C ) are representative of three
similar experiments.
co
n
tr
o
l
actin
Bcl-XL
A B
48
33
28
PB PB
 +
 c
ha
se
co
n
tr
o
l
PB PB
 +
 c
ha
se
actin
caveolin-1
co
n
tr
o
l
PBC
Figure 4. Reversible suppression of Bcl -XL but not caveolin - 1 by PB.
Western blots of Bcl -XL from (A ) PC3 cells or (B ) DU -145 cells that were
ether mock - treated ( control ) , treated with 2 mM PB for 24 hours (PB ) , or
treated with 2 mM PB for 24 hours followed by a 24 -hour chase in the absence
of PB (PB+chase ) . (C ) Same treatment as in (A ) and (B ) but with
Western blot analysis of caveolin -1 using DU-145 cells.
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Secretion of VEGF from Prostate Cancer Cells is Attenuated
by PB
The VEGF is critical in tumor angiogenesis [33] . As cells
become hypoxic in a growing tumor, secretion of VEGF
stimulates vascularization. Prostate cancer cell lines have
been shown to express high levels of VEGF [38] and its
expression positively correlates to the stage, grade, and
clinical outcome of prostate cancer [39] . The PC3 cells have
been shown to express more cytosolic VEGF than DU-145
cells, which in turn express more VEGF than LNCaP cells
[38] . In this study, we used an ELISA technique to measure
the amount of VEGF secreted by these cells in culture. We
found that compared to PC3 cells, the DU-145 cells secreted
64% and the LNCaP cells secreted about 20% of VEGF into
the culture media when normalized to the same number of
cells (data not shown). Thus, the ranking order of VEGF
secretion observed in this study matched the ranking order of
VEGF cell staining of these cells as shown previously [38] .
Because the LNCaP cells secreted low levels of VEGF and
were less reliably measured, we decided not to include them
in the PB experiments described below.
We next investigated whether PB affects the expression
of secreted VEGF in the media of cultured PC3 and DU-145
cells. Cells were mock- treated or incubated in the presence
of 2 mM PB for 24 hours. The conditioned media was then
collected and the abundance of VEGF was determined using
an ELISA kit (R&D Systems) . It was found that PB reduced
the amount of VEGF to 60% and 70% compared to the
mock- treated samples for the PC3 and DU-145 cells,
respectively (Figure 5 ) . We also simulated hypoxia by
treating the cells for 24 hours with cobalt chloride [40] . This
marginally increased the amount of secreted VEGF to 104%
in the PC3 cells and to 122% in DU-145 cells. When cells
were incubated simultaneously with both cobalt chloride and
PB, the VEGF levels dropped to 55% and 66% for PC3 and
DU-145 cells, respectively (Figure 5 ) . Thus, PB significantly
reduced the amount of VEGF secreted from these prostate
cancer cells both under normal and hypoxia-simulated
conditions.
Interaction between Ionizing Radiation and PB in the
Induction of Apoptosis
We have previously shown that butyrate and ionizing
radiation can act in synergy to induce apoptosis in human
fibroblasts [16] . This radiosensitizing effect by butyrate
correlated with a reduction in the protein levels of Bcl -XL. In
this study, we show that in addition to an attenuation of the
expression of Bcl -XL in prostate cancer cells, the double-
strand break repair protein DNA-PK is greatly reduced by
PB. The reduced protein levels of Bcl -XL and DNA-PK
would be expected to sensitize these cells further to the
cytotoxic affects of ionizing radiation because cells that lack
DNA-PK activity are extremely sensitive to ionizing radiation
[41] . However, PB induces cell cycle arrest by increasing the
5% 6% 20%
IR PB IR+PB
Figure 6. PB acts in synergy with ionizing radiation to induce apoptosis in DU-145 prostate cancer cells. DU -145 cells were treated with 2 mMPB or irradiated with 2
Gy of ionizing radiation and incubated for 72 hours in the absence or presence of 2 mM PB. Cells were then collected and fixed, stained with propidium iodide, and
analyzed for the percentage of cells with a sub -G1 DNA content using flow cytometry.
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Figure 5. PB reduces the secretion of VEGF from cells grown under normal or
hypoxic - simulated conditions. Cells were mock - treated, treated with 2 mM
PB, treated with 100 MCoCl2 or with the combination of 100 MCoCl2 and 2
mM PB. The levels of VEGF secreted into the growth media were determined
using ELISA. The values are expressed as relative values of the mock - treated
cells and they represent the average of three independent experiments with
error bars showing the standard error of the mean (S.E.M. ) . Statistical
analysis showed that the PB- treated cells secreted significantly less amounts
of VEGF (stars ) than controls (P< .05 ) .
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expression of p21WAF1 [42] and this may partially protect
cells from subsequent exposure to ionizing radiation. In fact,
we have observed that more apoptosis is induced if the
butyrate exposure is scheduled to occur after, rather then
prior to, irradiation [16] . Furthermore, it has been shown that
the duration of butyrate treatment prior to radiation is
important for whether butyrate acts as a radiosensitizer
(72-hour pretreatment) or radioprotector (24-hour pretreat-
ment) [43] .
To test whether the apoptosis- inducing ability of ionizing
radiation could be potentiated in prostate cancer cells by PB,
we irradiated DU-145 cells with 2 Gy and then incubated the
cells for 72 hours in the presence or absence of 2 mM PB.
Flow cytometric analysis of DNA content revealed that
neither PB nor irradiation alone induced significant amounts
of apoptosis during this time period (Figure 6 ) . However,
when the irradiated cells were subsequently incubated in
with PB for 72 hours, an increased amount of apoptosis was
observed. Thus, ionizing radiation and PB appear to act in
synergy to induce apoptosis in prostate cancer cells.
Discussion
In this study, we show that the histone deacetylase inhibitor
PB attenuated the protein expression of Bcl -XL, DNA-PK,
caveolin-1, and VEGF in prostate cancer cell lines.
Incubation of the PC3, DU-145, and LNCaP cell lines with
the clinically achievable dose of 2 mM PB [21,44] reduced
the protein levels of Bcl -XL to about 40% within 24 hours
(Figure 1 and data not shown). Furthermore, the protein
expression of DNA-PK and caveolin-1 was reduced to
below 20% within 48 hours (Figure 3 ) and the secretion of
VEGFwas reduced by about 40%within 24 hours in PC3 and
DU-145 cells.
It is expected that both the cellular levels of Bcl -XL and
DNA-PK would influence the response of cancer cells to
radiation or chemotherapy. Bcl -XL, a member of the Bcl -2
family of apoptosis regulators, antagonizes apoptosis by
promoting mitochondrial membrane permeability, thus pre-
venting the release of cytochrome c [45,46] . Bcl -XL is
frequently overexpressed in tumors, making these cells more
resistant to chemotherapy [47–49] . The DNA-PK is a
critical component of both the DNA double-strand break-
repair machinery and in V(D)J recombination [41] . Cells
lacking DNA-PK catalytic activity are defective in DNA
double-strand break-repair and extremely sensitive to the
effects of ionizing radiation. Increased cellular levels of
DNA-PK have been shown to protect cells against the toxic
effects of ionizing radiation, adriamycin, bleomycin, and
cisplatin [50] . Interestingly, it was recently reported that
sodium butyrate severely inhibits DNA double-strand break-
repair in human lymphocytes [51] . Furthermore, in this
study, we show that PB sensitizes prostate cancer cells to
ionizing radiation– induced apoptosis (Figure 6 ) . Thus, it is
possible that the attenuation of the expression of DNA-PK in
prostate cancer cells by PB contributes to a reduced repair of
DNA double-strand breaks induced by ionizing radiation and
that the reduced expression of Bcl -XL contributes to the
lowering of the apoptotic threshold. Taken together, these
findings should stimulate efforts to investigate the efficacy of
combining PB with radiation or chemotherapy for the
treatment of prostate cancer.
Caveolin-1 is highly expressed in prostate cancer cells
and has been shown to positively correlate to stage, grade,
and clinical outcome of prostate cancer [52] . Caveolin -1 is
thought to regulate integrin signaling pathways [53] , and the
reduction of its expression by antisense cDNA has been
shown to convert androgen- insensitive metastatic prostate
cancer cells into androgen-sensitive cells [54] . In prelimi-
nary studies using the sea urchin embryo invasion assay
[55,56] , we have found that PB efficiently blocks the
invasive properties of both DU-145 and PC3 cells (E. Dyer
et al., unpublished observation) . Whether this is due to the
downregulation of caveolin-1 or the inhibition of some other
gene product involved in invasiveness, such as urokinase
[18] , has to be elucidated.
VEGF is critical for tumor angiogenesis [33] . Similar to
caveolin-1, VEGF is highly expressed in prostate cancer
cells and has been shown to positively correlate to stage,
grade, and clinical outcome of prostate cancer [39] . The
downregulation of VEGF by PB found in this study, together
with the findings that butyrate can directly inhibit the
proliferation of endothelial cells without affecting viability
[57] , suggests that butyrate and PB may have anti -
angiogenic properties. Furthermore, it has been shown that
anti -VEGF treatments potentiate the sensitivity of tumor
cells to ionizing radiation both in vitro and in vivo [58–60] .
Thus, PBmay sensitize tumor cells to ionizing radiation by its
effects on both angiogenesis by downregulation of VEGF
and DNA damage processing and apoptosis by down-
regulation of DNA-PK and Bcl-XL.
PB and other butyrate derivatives have been recognized
as potential anticancer agents [19–21] . Our results that PB
suppresses the expression of Bcl -XL, DNA-PK, caveolin-1,
and VEGF should stimulate further studies investigating the
potential usefulness of PB as an anticancer agent especially
when combined with radiation or other cancer therapeutics.
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